Asthma is a serious, increasing public health problem in many countries throughout the world and constitutes a major economic burden [1,2]. Undertreatment with antiinflammatory preparations is regarded as one of the factors potentially responsible for the apparent increase of asthma morbidity and mortality. A number of studies have attempted to shed light on asthma care in different countries by using data from general practice registers, national medical expenditures and indirect costs, antiasthma drug sales, pharmacists or community pharmacy records [3][4][5][6]. The estimates drawn from these studies are inevitably approximate.More recently, this issue has been better approached by measuring antiasthmatic drug consumption and the use of healthcare resources by asthmatic patients identified through adequate epidemiological or clinical surveys [7,8].Based on the results of a screening questionnaire administered in the first phase of the European Community Respiratory Health Survey (ECRHS), a multicentre survey of the prevalence, determinants and management of asthma [9,10], we found Italy to be one of the countries with the lowest ratio (0.54) between subjects declaring current consumption of antiasthmatic drugs and those reporting asthma attacks during the previous 12 months [11,12]. In the second phase of the ECRHS, carried out in three Italian cities (Pavia, Turin and Verona), a standardized clinical interview was used to improve the identification of asthmatic subjects and to obtain a more precise estimate of antiasthmatic drug consumption.The aim of this study was to assess whether and, if so, to what extent, there is inadequate use of antiasthmatic preparations in the north of Italy.
Materials and methodsThe design of the ECRHS has been described elsewhere [9,10]. Briefly, in phase 1, a screening questionnaire on respiratory symptoms and use of asthma medication was mailed to a probability sample of 20-44 yr old people resident in three Italian cities. There was an 86% (6,031 subjects) response rate to this phase of the survey [12]. In phase 2, a 20% random sample of subjects who responded to the questionnaire were invited to attend the local chest clinic, in order to undergo a standardized clinical interview as well as lung function and allergy tests.A total of 1,835 subjects out of 6,031 who had returned the screening questionnaire were invited to attend the clinics. Of these subjects, 914 participated in phase 2. The general demographic and socioeconomic characteristics of subjects participating or not participating in phase 2 were similar and representative of the three cities. GivenInadequate antiasthma drug use in the north of Italy. I. Cerveri, M.C. Zoia, M. Bugiani, A. Corsico, A. Carosso, P. Piccioni, L. Casali, R. De Marco. ERS Journals Ltd 1997. ABSTRACT: A multicentre survey of prevalence, determinants and management of asthma (the European Community Respiratory Health Survey (ECRHS)) has shown that the ratio of subjects declaring current use of antiasthmatic drugs to those reporting asthma ...